Table 1 Characteristics and therapies of patients with eosinophilic granulomatosis with polyangiitis (EGPA) or chronic eosinophilic pneumonia (CEP)

Age (y), mean ± 1 SD

41.8 ± 15.9

44.2 ± 17.0

NS^a

Sex (M/F)

7/10

6/6

NS^b

Type: atopy/nonatopy

8/9

4/8

NS^b

Allergic rhinitis (yes/no)

9/7

7/5

NS^b

Atopic dermatitis (yes/no)

4/13

2/10

NS^b

Age at onset asthma (y), mean ± SD

34.5 ± 14.3

36.3 ± 14.4

NS^a

Astham severity Step 1/2/3/4

1/0/5/11

2/0/3/8

NS^b

Daily dose of ICS (mg; converted to CFC-BDP equivalents)

1482.4 ± 656.0

1173.3 ± 812.3

NS^a

 Asthma

100

100

NS^b

 Paranasal sinusitis

94.1

83.3

NS^b

 Multiple polyneuropathy

100

0

<0.01^b

 Pulmonary infiltrates

88.2

100

NS^b

 Myocardinal involvement

76.5

0

<0.01^b

 Liver, gall bladder, pancreas

17.6

0

NS^b

 Renal involvement^c

41.2

0

< 0.05^b

  Proteinuria

41.2

0

< 0.05^b

  Nephritis or nephrosis

11.8

0

NS^b

 Skin involvement

88.2

25

< 0.01^b

 Arthritis

52.9

0

< 0.01^b

 Myalgia

29.4

0

< 0.05^b

 Central nervous system involvement

29.4

0

< 0.05^b

 Clinical symptoms on the upper abdominal region (yes/no)

10/7

3/9

NS^b

 Clinical symptoms on the lower abdominal region (yes/no)

12/5

8/4

NS^b

 Positive signs on mucous membrane of the upper digestive organs by stomach endscope (yes/no)

10/7

2/10

< 0.05^b

 Positive signs on mucous membrane of the large intestine by colon endscope (yes/no)

8/9

5/7

NS^b

 Systemic corticosteroids (yes/no)

17/0

5/7

< 0.01^b

 Prednisolone per day for initial dose (mg), mean ± 1 SD

45.5 ± 10.7

20.2 ± 5.5

< 0.01^a

 Patients taking an immunosuppressant (%)

76.5

0

< 0.01^b

 CYC/AZA/CSA

6/3/4

0/0/0

 IVIG (yes/no)

9/8

0/12

< 0.01^b